Cas:24345-02-6 zinc(II) 4-methylbenzenesulfinate manufacturer & supplier

We serve Chemical Name:zinc(II) 4-methylbenzenesulfinate CAS:24345-02-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

zinc(II) 4-methylbenzenesulfinate

Chemical Name:zinc(II) 4-methylbenzenesulfinate
CAS.NO:24345-02-6
Synonyms:Zinc bis(p-toluenesulphinate);P-Toluene sulfinic acid zinc salt;zinc 4-methylbenzenesulfinate;zinc bis(4-methylbenzenesulfinate)
Molecular Formula:C14H14O4S2Zn
Molecular Weight:375.76900
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:340ºC at 760mmHg
Density:1.36g/cm3
Index of Refraction:
PSA:118.68000
Exact Mass:373.96200
LogP:4.19490

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Zinc bis(p-toluenesulphinate) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,zinc bis(4-methylbenzenesulfinate) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Zinc bis(p-toluenesulphinate) Use and application,Zinc bis(p-toluenesulphinate) technical grade,usp/ep/jp grade.


Related News: The April halt followed the discovery that ingredients from AstraZeneca’s (AZN.L) COVID-19 vaccine, also being produced at the plant at the time, contaminated a batch of J&J’s vaccine. AstraZeneca’s shot is no longer being made there. zinc(II) 4-methylbenzenesulfinate manufacturer After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API. zinc(II) 4-methylbenzenesulfinate supplier The agency said it was not yet ready to authorize Emergent BioSolutions Inc’s (EBS.N) plant for manufacturing the J&J vaccine. zinc(II) 4-methylbenzenesulfinate vendor Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. zinc(II) 4-methylbenzenesulfinate factory This is very visible in herbal medicines in which the API is frequently a combination of several mixtures and/or substances which when used together cause pharmacological activity on the body.